Benchmark starts Insulet at Buy

|About: Insulet Corporation (PODD)|By:, SA News Editor

Benchmark sees a 22% upside for shares of Insulet (PODD) as analyst Jan Wald says an active third manufacturing line will likely alleviate tight OmniPod inventory.

"We believe that greater customer retention, better market penetration as evidenced by new prescribers and improved margins from the new OmniPod insulin pump should drive upside in the shares," Wald adds.

Shares initiated at Buy, price target is $44.